PapersTrialsTopicsCompoundsCountriesStakeholdersPeopleCoursesEvents
Browse all papers

Latest papers

Long-term efficacy of psilocybin with adjunct psychotherapy in treatment-resistant depressionPsilocybin · Treatment-resistant depressionDrug-drug interactions between psychiatric medications and MDMA or psilocybinMDMA & psilocybin · SafetyAn international mega-analysis of psychedelic drug effects on brain circuit functionCross-compound · NeuroimagingEsketamine in treatment-resistant depression with and without comorbid borderline personalityEsketamine · Treatment-resistant depression

Featured

Road to Access

Science, regulation, and economics on the path to patient access.

01Evidence02Approval03Reimbursement04Delivery05Access—Big Picture
Start the journey
ResultsCompare outcome data across trials and publications.Research SnapshotOne-page overview of trials, participants, papers, and research networks.Clinical GuidelinesTrial-anchored manuals and protocol guidance with competency mapping.Research recapsMonthly evidence summaries with key takeaways.Map of researchLandscape view of trials, compounds, and outcomes.NewsletterWeekly or daily updates on trials, publications, analysis, and more.Research GroupsWorldwide map of psychedelic research centres by region.Research NetworkInteractive co-authorship map of psychedelic researchers.Top papersFind needles in the haystack of psychedelic research per topic.
AskBeta
Pricing
Back to journals
Academic JournalOpen Access

PLOS Global Public Health

1 Papers Indexed in Blossom

Data updated June 16, 2026

Research Footprint

PLOS Global Public Health has 1 tracked paper indexed in Blossom (2022) from 8 authors, most often covering Ayahuasca, across Anxiety Disorders, Substance Use Disorders (SUD) and Public Health, Prevention & Behaviour Change.

Published Papers

Open Accessindividual

Adverse effects of ayahuasca: Results from the Global Ayahuasca Survey

A global survey of 10,836 ayahuasca users reported high rates of acute physical effects (69.9%, chiefly vomiting) and medium-term psychological effects (55.9%), though most users framed psychological effects as part of a positive integration process and only small proportions required medical (2.3%) or professional (≈12%) help. Risk factors for physical adverse effects included older age at first use, physical health conditions, greater use, prior substance use disorder and unsupervised settings, while mental health effects were linked to anxiety disorders, physical conditions and stronger spiritual experiences but were less common in religious contexts, suggesting targets for screening, support and policy.

Published
November 16, 2022
Journal
PLOS Global Public Health
Authors
Bouso, J. C., Andión, O., Sarris, J., Scheidegger, M., Tófoli, L.F., Opaleye, E. S., Schubert, V., Perkins, D.

Quick Facts

Papers Indexed
1
h-Index
24
Open Access
Yes
Publisher
Public Library of Science
Country
United States
Website
Visit

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.